Independent consultant Boston Healthcare Associates modelled the budget impact of using PromarkerD compared to the current standard of care, to proactively test for diabetic kidney disease in patients with type 2 diabetes but who otherwise have no sign of kidney disease. It found the test — developed by Proteomics International — could result in net savings to Medicare and commercial insurers of USD384 billion over 10 years.
The company presented this data as a poster abstract at the American Diabetes Association’s 81st Scientific Sessions.